Gout Management: Tailored to Age of Onset – Study Reveals
- Gout, characterized by the deposition of monosodium urate crystals in joints, manifests differently depending on when the condition first develops.
- A prospective cohort study utilizing data from the Urate Lowering TheRApy in gout (ULTRA) registry examined these differences.The study, which included 477 patients aged 18 and older meeting...
- The older-onset group exhibited a considerably different profile compared to those with common-age-of-onset gout.
Understanding the Differences in Older-Onset Gout
Table of Contents
Gout Presentation Varies with Age of Onset
Gout, characterized by the deposition of monosodium urate crystals in joints, manifests differently depending on when the condition first develops. Recent research highlights key distinctions between gout occurring in older adults versus those diagnosed at a more typical age.
Study Details and Patient Demographics
A prospective cohort study utilizing data from the Urate Lowering TheRApy in gout (ULTRA) registry examined these differences.The study, which included 477 patients aged 18 and older meeting the 2015 American College of Rheumatology/European League Against Rheumatism classification criteria for gout, categorized participants as having either older-onset gout (age 65 or older) or common-age-of-onset gout (diagnosed before age 65). The analysis revealed that 22% of patients had older-onset gout, while 78% had common-age-of-onset gout. Baseline and 6-month data were collected on demographics, clinical features, treatment patterns, quality of life, and laboratory findings.
Key Differences Observed
The older-onset group exhibited a considerably different profile compared to those with common-age-of-onset gout. Notably, older-onset gout was more prevalent in women (25.7% versus 2.4%). Furthermore, patients with older-onset gout demonstrated a higher incidence of gout-related joint damage (30.5% compared to 19.6%).
Comorbidities and Treatment Approaches
Individuals with older-onset gout also experienced a greater frequency of co-existing health conditions, including hypertension, cardiovascular disease, chronic kidney disease, and malignancies. Febuxostat, a medication used to lower uric acid levels, was prescribed more often in the older-onset group (71.4% versus 58.9%). However, the dosages administered to the older-onset group tended to be lower.
Implications for Clinical Practise
These findings underscore the importance of considering age of onset when managing gout. The increased prevalence of comorbidities in older adults with gout suggests a need for a holistic approach to care, addressing not only uric acid levels but also related health concerns. The tendency towards lower febuxostat dosages in this population highlights the need for careful titration and monitoring to optimize treatment efficacy and minimize potential side effects.